Harbour BioMed starts HBM4003 dosing in Phase I solid tumours trial
Developed from Harbour Mice, HBM4003 is a human monoclonal heavy chain only antibody that acts against cytotoxic T-lymphocyte-associated protein 4…
11 May 2021
Aurinia’s Lupkynis improves renal response rates in lupus nephritis trial
Trial data showed that Lupkynis (voclosporin) plus standard of care (SoC) of mycophenolate mofetil (MMF) and low-dose corticosteroids offered statistically superior complete renal response (CR) rates versus SoC alone at…
11 May 2021
Ampio gets approval to begin Phase I trial for long-haul Covid-19
Ampio Pharmaceuticals has secured Investigational Review Board (IRB) approval for its Phase I trial against long-haul Covid-19. Named AP-018, the trial will assess the use of inhaled Ampion to treat…
11 May 2021
Altimmune’s intranasal Covid-19 vaccine shows sterilising immunity
A preclinical study of Altimmune's single-dose intranasal Covid-19 vaccine, AdCOVID, has demonstrated positive results, with no detectable levels of infectious virus in the lungs of vaccinated mice after challenge with…
10 May 2021
Telix begins Phase III prostate cancer treatment trial
Telix Pharmaceuticals has begun a Phase III ProstACT clinical trial of its therapy candidate, TLX591 (177Lu-DOTA-rosopatamab), in advanced metastatic castrate-resistant prostate cancer (mCRPC) patients. The trial initiation comes after approval…
10 May 2021
AstraZeneca’s combination therapy shows overall survival benefit in NSCLC
A human monoclonal antibody (mAb), Imfinzi attaches to programmed death-ligand 1 (PD-L1) while Tremelimumab, also a human mAb, hinders cytotoxic T-lymphocyte-associated protein 4’s (CTLA-4) activity. The randomised, open-label, multi-centre, global Phase III POSEIDON trial…
07 May 2021
Florence raises funds to advance clinical trial connectivity
Led by Insight Partners, the financing round was joined by existing investors Fulcrum Equity Partners, Bee Partners, and Flashpoint. The proceeds from the funding will aid Florence to better connect…
© Copyright Verdict Media Limited 2021
Powered by
